Cardiovascular Safety in Drug Development: State-of-the-Art Assessments

Posted:
25
March 2011

Join Richmond Pharmacology at this year�s Cardiovascular Safety in Drug Development: State-of-the-Art Assessments, taking place in Washington, USA from April 14 to 15.Featured topics will include QT issues in drug development, New approaches to QT analysis, Phase 3 development when there is a QT signal, Post-marketing surveillance, Ischemic events, Bleeding, Blood pressure and In what situations outcomes studies are necessary.Richmond Pharmacology�s CEO, Dr Jorg Taubel will be presenting the abstract; Can Food Serve as a Non-pharmacological Control in Thorough Cardiac Safety Studies, on Day 1, Session 3. This presentation will provide an insight into the effect of food on heart rate under the conditions of a Thorough QT (TQT) study. Dr Taubel has worked in clinical pharmacology for over 20 years and has been involved in the conduct of more than 400 early phase studies.For a detailed schedule of the meeting please click hereChaired by Dr Philip T. Sager, the meeting will feature presentations and commentary from leading industry, academic and regulatory speakers with advice on how to optimize cardiovascular safety assessment. For information on how to register for the conference click hereIf you would like to meet with Dr Taubel to discuss your QT requirements and how Richmond Pharmacology can help develop your program please email us at info@richmondpharmacology.com and we will try our best to accommodate your request. Be assured that your study will be managed by experts with unparalleled clinical excellence.We hope to see you in Washington to learn more about Richmond Pharmacology and what you can expect from Europe�s leading Early Phase Full-Service CRO.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more